• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Zentalis Pharmaceuticals Inc.

    11/14/24 4:20:13 PM ET
    $ZNTL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZNTL alert in real time by email
    SC 13G/A 1 tm2427061d18_sc13ga.htm SC 13G/A

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G*

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO § 240.13d-2

    (Amendment No. 2)*

     

     

    Zentalis Pharmaceuticals, Inc.
    (Name of Issuer)
     
    Common Stock, $0.001 par value per share (the “Shares”)
    (Title of Class of Securities)
     
    98943L107
    (CUSIP Number)
     
    September 30, 2024
    (Date of Event Which Requires Filing of the Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    o Rule 13d-1(b)
    x Rule 13d-1(c)
    o Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    CUSIP No. 98943L107 13G Page 2 of 13 Pages

     

     

    1.

    NAME OF REPORTING PERSONS

     

    Citadel Advisors LLC

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)     o

    (b)     o

     

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    2,630,035 Shares

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    See Row 6 above

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    See Row 6 above

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    o

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    3.7%1

    12.

    TYPE OF REPORTING PERSON

     

    IA; OO; HC

           

     

    _________________________

    1 The percentages reported in this Schedule 13G are based upon 71,107,967 Shares outstanding as of August 7, 2024 (according to the issuer’s Form 10-Q as filed with the Securities and Exchange Commission on August 9, 2024).

     

     

     

     

    CUSIP No. 98943L107 13G Page 3 of 13 Pages

     

     

    1.

    NAME OF REPORTING PERSONS

     

    Citadel Advisors Holdings LP

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)     o

    (b)     o

     

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    2,630,035 Shares

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    See Row 6 above

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    See Row 6 above

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    o

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    3.7%

    12.

    TYPE OF REPORTING PERSON

     

    PN; HC

           

     

     

     

     

    CUSIP No. 98943L107 13G Page 4 of 13 Pages

     

     

    1.

    NAME OF REPORTING PERSONS

     

    Citadel GP LLC

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)     o

    (b)     o

     

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    2,630,035 Shares

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    See Row 6 above

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    See Row 6 above

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    o

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    3.7%

    12.

    TYPE OF REPORTING PERSON

     

    OO; HC

           

     

     

     

     

    CUSIP No. 98943L107 13G Page 5 of 13 Pages

     

     

    1.

    NAME OF REPORTING PERSONS

     

    Citadel Securities LLC

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)     o

    (b)     o

     

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    107,186 Shares

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    See Row 6 above

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    See Row 6 above

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    o

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.2%

    12.

    TYPE OF REPORTING PERSON

     

    BD; OO

           

     

     

     

     

    CUSIP No. 98943L107 13G Page 6 of 13 Pages

     

     

    1.

    NAME OF REPORTING PERSONS

     

    Citadel Securities Group LP

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)     o

    (b)     o

     

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    107,186 Shares

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    See Row 6 above

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    See Row 6 above

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    o

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.2%

    12.

    TYPE OF REPORTING PERSON

     

    PN; HC

           

     

     

     

     

    CUSIP No. 98943L107 13G Page 7 of 13 Pages

     

     

    1.

    NAME OF REPORTING PERSONS

     

    Citadel Securities GP LLC

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)     o

    (b)     o

     

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    107,186 Shares

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    See Row 6 above

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    See Row 6 above

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    o

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.2%

    12.

    TYPE OF REPORTING PERSON

     

    OO; HC

           

     

     

     

     

    CUSIP No. 98943L107 13G Page 8 of 13 Pages

     

     

    1.

    NAME OF REPORTING PERSONS

     

    Kenneth Griffin

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)     o

    (b)     o

     

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    U.S. Citizen

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    2,737,221 Shares

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    See Row 6 above

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    See Row 6 above

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    o

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    3.9%

    12.

    TYPE OF REPORTING PERSON

     

    IN; HC

           

     

     

     

     

    CUSIP No. 98943L107 13G Page 9 of 13 Pages

     

     

    Item 1(a). Name of Issuer:
       
      Zentalis Pharmaceuticals, Inc.
       
    Item 1(b). Address of Issuer’s Principal Executive Offices:
       
      10275 Science Center Dr., Suite 200, San Diego, California 92121 
       
    Item 2(a). Name of Person Filing:
       
      This Schedule 13G is being jointly filed by Citadel Advisors LLC (“Citadel Advisors”), Citadel Advisors Holdings LP (“CAH”), Citadel GP LLC (“CGP”), Citadel Securities LLC (“Citadel Securities”), Citadel Securities Group LP (“CALC4”), Citadel Securities GP LLC (“CSGP”) and Mr. Kenneth Griffin (collectively with Citadel Advisors, CAH, CGP, Citadel Securities, CALC4 and CSGP, the “Reporting Persons”) with respect to the Shares of the above-named issuer owned by Citadel Multi-Strategy Equities Master Fund Ltd., a Cayman Islands company (“CM”), and Citadel Securities. Such owned Shares may include other instruments exercisable for or convertible into Shares.
       
      Citadel Advisors is the portfolio manager for CM. CAH is the sole member of Citadel Advisors. CGP is the general partner of CAH. CALC4 is the non-member manager of Citadel Securities.  CSGP is the general partner of CALC4.  Mr. Griffin is the President and Chief Executive Officer of CGP, and owns a controlling interest in CGP and CSGP.
       
      The filing of this statement shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any securities covered by the statement other than the securities actually owned by such person (if any).
       
    Item 2(b). Address or Principal Business Office or, if none, Residence:
       
      The address of each of the Reporting Persons is Southeast Financial Center, 200 S. Biscayne Blvd., Suite 3300, Miami, Florida 33131.
       
    Item 2(c). Citizenship:
       
      Each of Citadel Advisors, CGP, Citadel Securities and CSGP is organized as a limited liability company under the laws of the State of Delaware.  Each of CALC4 and CAH is organized as a limited partnership under the laws of the State of Delaware.  Mr. Griffin is a U.S. citizen.
       
    Item 2(d). Title of Class of Securities:
       
      Common Stock, $0.001 par value per share
       
    Item 2(e). CUSIP Number:
       
      98943L107

     

     

     

     

    CUSIP No. 98943L107 13G Page 10 of 13 Pages

     

     

    Item 3. If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:
       
      (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
      (e) ¨ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
      (f) ¨ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
      (g) ¨ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
      (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
      (i) ¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
      (j) ¨ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with § 240.13d-1(b)(1)(ii)(K).
             
      If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____________.
             
    Item 4. Ownership:
             
      A. Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC
             
        (a) Each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC may be deemed to beneficially own 2,630,035 Shares.
             
        (b) The number of Shares that each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC may be deemed to beneficially own constitutes 3.7% of the Shares outstanding.
             
        (c) Number of Shares as to which such person has:
             
          (i) sole power to vote or to direct the vote:  0
             
          (ii) shared power to vote or to direct the vote:  2,630,035
             
          (iii) sole power to dispose or to direct the disposition of:  0
             
          (iv) shared power to dispose or to direct the disposition of:  2,630,035

     

     

     

     

    CUSIP No. 98943L107 13G Page 11 of 13 Pages

     

     

      B. Citadel Securities LLC
             
        (a) Citadel Securities LLC may be deemed to beneficially own 107,186 Shares.
           
        (b) The number of Shares that Citadel Securities LLC may be deemed to beneficially own constitutes 0.2% of the Shares outstanding.
           
        (c) Number of shares of Shares as to which such person has:
           
          (i) sole power to vote or to direct the vote:  0
             
          (ii) shared power to vote or to direct the vote:  107,186
             
          (iii) sole power to dispose or to direct the disposition of:  0
             
          (iv) shared power to dispose or to direct the disposition of:  107,186
             
      C. Citadel Securities Group LP and Citadel Securities GP LLC
             
        (a) Each of Citadel Securities Group LP and Citadel Securities GP LLC may be deemed to beneficially own 107,186 Shares.
           
        (b) The number of Shares that each of Citadel Securities Group LP and Citadel Securities GP LLC may be deemed to beneficially own constitutes 0.2% of the Shares outstanding.
           
        (c) Number of Shares as to which such person has:
           
          (i) sole power to vote or to direct the vote:  0
             
          (ii) shared power to vote or to direct the vote:  107,186
             
          (iii) sole power to dispose or to direct the disposition of:  0
             
          (iv) shared power to dispose or to direct the disposition of:  107,186
             

     

     

     

     

    CUSIP No. 98943L107 13G Page 12 of 13 Pages

     

     

      D. Kenneth Griffin
             
        (a) Mr. Griffin may be deemed to beneficially own 2,737,221 Shares.
           
        (b) The number of Shares that Mr. Griffin may be deemed to beneficially own constitutes 3.9% of the Shares outstanding.
           
        (c) Number of Shares as to which such person has:
           
          (i) sole power to vote or to direct the vote:  0
             
          (ii) shared power to vote or to direct the vote:  2,737,221
             
          (iii) sole power to dispose or to direct the disposition of:  0
             
          (iv) shared power to dispose or to direct the disposition of:  2,737,221

     

    Item 5. Ownership of Five Percent or Less of a Class:
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following. x
       
    Item 6. Ownership of More Than Five Percent on Behalf of Another Person:
       
      Not Applicable
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:
       
      Not Applicable
       
    Item 8. Identification and Classification of Members of the Group:
       
      Not Applicable
       
    Item 9. Notice of Dissolution of Group:
       
      Not Applicable
       
    Item 10. Certifications:
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    CUSIP No. 98943L107 13G Page 13 of 13 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of its knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

     

    Dated November 14, 2024.

     

    CITADEL SECURITIES LLC   CITADEL ADVISORS LLC  
               
    By: /s/ Guy Miller   By: /s/ Seth Levy  
      Guy Miller, Authorized Signatory     Seth Levy, Authorized Signatory  
               
               
    CITADEL SECURITIES GROUP LP   CITADEL ADVISORS HOLDINGS LP  
               
    By: /s/ Guy Miller   By: /s/ Seth Levy  
      Guy Miller, Authorized Signatory     Seth Levy, Authorized Signatory  
               
               
    CITADEL SECURITIES GP LLC   CITADEL GP LLC  
               
    By: /s/ Guy Miller   By: /s/ Seth Levy  
      Guy Miller, Authorized Signatory     Seth Levy, Authorized Signatory  
               
               
          KENNETH GRIFFIN  
               
          By: /s/ Seth Levy  
            Seth Levy, attorney-in-fact*  

     

     

    _________________________

    * Seth Levy is signing on behalf of Kenneth Griffin as attorney-in-fact pursuant to a power of attorney previously filed with the Securities and Exchange Commission, and hereby incorporated by reference herein.  The power of attorney was filed as an attachment to a filing by Citadel Advisors LLC on Schedule 13G for Allakos Inc. on October 13, 2023.

     

     

     

    Get the next $ZNTL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ZNTL

    DatePrice TargetRatingAnalyst
    8/12/2024$4.00Underperform → Neutral
    Wedbush
    6/20/2024$28.00 → $5.00Buy → Neutral
    UBS
    6/18/2024$42.00 → $6.00Buy → Hold
    Jefferies
    6/18/2024$38.00 → $8.00Overweight → Equal-Weight
    Morgan Stanley
    6/18/2024$15.00 → $4.00Neutral → Underperform
    Wedbush
    6/18/2024Overweight → Equal Weight
    Wells Fargo
    11/8/2023$38.00 → $12.00Outperform → Neutral
    Wedbush
    11/7/2023$15.00Outperform → Market Perform
    Leerink Partners
    More analyst ratings

    $ZNTL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress

      First patient dosed in DENALI Part 2a clinical trial of azenosertib in patients with Cyclin E1+ PROC Topline data from DENALI Part 2 anticipated by year end 2026 with the potential to support an accelerated approval, subject to FDA feedback $332.5 million cash, cash equivalents and marketable securities supports operational runway into late 2027 SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, announced financial results for the first quarter 2025 and highlighted recent oper

      5/14/25 4:05:00 PM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on May 1, 2025, the Compensation Committee of Zentalis' Board of Directors granted non-qualified stock options to purchase an aggregate of 14,000 shares of the Company's common stock to one (1) newly hired employee. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to such individual's entering

      5/1/25 5:00:00 PM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC

      Phase 2 registration-intent trial enrolling Part 2a dose confirmation arms Topline data from DENALI Part 2 anticipated by year end 2026 with the potential to support an accelerated approval, subject to FDA feedback SAN DIEGO, April 28, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that the first patient has been dosed in Part 2 of the Phase 2 DENALI clinical trial (NCT05128825) of azenosertib in patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC). As previously d

      4/28/25 8:00:00 AM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZNTL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Myers Scott Dunseth bought $29,373 worth of shares (21,000 units at $1.40), increasing direct ownership by 8% to 281,192 units (SEC Form 4)

      4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)

      4/30/25 5:07:20 PM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Bruns Ingmar bought $45,656 worth of shares (20,000 units at $2.28), increasing direct ownership by 120% to 36,629 units (SEC Form 4)

      4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)

      2/12/25 5:00:31 PM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Skvarka Jan bought $103,446 worth of shares (60,000 units at $1.72), increasing direct ownership by 67% to 149,551 units (SEC Form 4)

      4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)

      2/4/25 4:45:00 PM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZNTL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Zentalis Pharmaceuticals Inc.

      SC 13G/A - Zentalis Pharmaceuticals, Inc. (0001725160) (Subject)

      11/14/24 4:20:13 PM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Zentalis Pharmaceuticals Inc.

      SC 13G/A - Zentalis Pharmaceuticals, Inc. (0001725160) (Subject)

      11/12/24 6:00:27 PM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Zentalis Pharmaceuticals Inc.

      SC 13G/A - Zentalis Pharmaceuticals, Inc. (0001725160) (Subject)

      11/6/24 2:47:51 PM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZNTL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Zentalis Pharma upgraded by Wedbush with a new price target

      Wedbush upgraded Zentalis Pharma from Underperform to Neutral and set a new price target of $4.00

      8/12/24 8:08:44 AM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zentalis Pharma downgraded by UBS with a new price target

      UBS downgraded Zentalis Pharma from Buy to Neutral and set a new price target of $5.00 from $28.00 previously

      6/20/24 7:40:40 AM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zentalis Pharma downgraded by Jefferies with a new price target

      Jefferies downgraded Zentalis Pharma from Buy to Hold and set a new price target of $6.00 from $42.00 previously

      6/18/24 2:21:55 PM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZNTL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Myers Scott Dunseth bought $29,373 worth of shares (21,000 units at $1.40), increasing direct ownership by 8% to 281,192 units (SEC Form 4)

      4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)

      4/30/25 5:07:20 PM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Bruns Ingmar bought $45,656 worth of shares (20,000 units at $2.28), increasing direct ownership by 120% to 36,629 units (SEC Form 4)

      4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)

      2/12/25 5:00:31 PM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PAO and Interim PFO Vultaggio Vincent was granted 158,586 shares and sold $4,476 worth of shares (2,615 units at $1.71), increasing direct ownership by 461% to 189,826 units (SEC Form 4)

      4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)

      2/5/25 6:33:02 PM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZNTL
    SEC Filings

    See more
    • Zentalis Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Zentalis Pharmaceuticals, Inc. (0001725160) (Filer)

      5/20/25 6:01:40 AM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by Zentalis Pharmaceuticals Inc.

      S-8 - Zentalis Pharmaceuticals, Inc. (0001725160) (Filer)

      5/14/25 4:15:53 PM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Zentalis Pharmaceuticals Inc.

      10-Q - Zentalis Pharmaceuticals, Inc. (0001725160) (Filer)

      5/14/25 4:13:06 PM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZNTL
    Leadership Updates

    Live Leadership Updates

    See more
    • Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates

      Positive azenosertib clinical data demonstrated clinically meaningful results in patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC) Topline data from registration-intent DENALI Part 2 anticipated by year end 2026 Strengthened management team to support execution of highly focused strategy $371.1 million cash, cash equivalents and marketable securities balance as of December 31, 2024, with projected cash runway into late 2027 SAN DIEGO, March 26, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and othe

      3/26/25 4:05:00 PM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zentalis Pharmaceuticals Announces Strategic Restructuring to Support Late-Stage Azenosertib Development

      Extended cash runway into late 2027, beyond a potentially registration-enabling azenosertib data readout from DENALI Part 2 Planned workforce reduction of approximately 40% of employees Corporate event to be held on January 29, 2025 at 8:00am ET to provide key updates on azenosertib clinical data, development and regulatory path SAN DIEGO, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced a restructuring of its business operations and research and development organ

      1/28/25 4:05:00 PM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zentalis Pharmaceuticals Announces Key Management Appointments

      SAN DIEGO, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Wendy Chang as Chief People Officer and Haibo Wang as Chief Business Officer. "Zentalis is sharply focused on our goal of bringing azenosertib to patients with gynecological malignancies," said Julie Eastland, Chief Executive Officer. "To support this goal, we are continuing to tune our leadership team and today announced the appointment of two talented leaders with a strong track record o

      12/12/24 7:00:00 AM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZNTL
    Financials

    Live finance-specific insights

    See more
    • Zentalis Pharmaceuticals Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer

      Results from DENALI Part 1b show an Objective Response Rate (ORR) of ~35% in response-evaluable, heavily-pretreated patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC) Across monotherapy cohorts in key clinical studies, well-characterized safety and tolerability profile shows no new safety signals Company aligned with FDA on seamless study design for DENALI Part 2 in patients with Cyclin E1+ PROC; study expected to begin 1H 2025 Topline data from registration-intent DENALI Part 2 anticipated by year end 2026 Management to host conference call today at 8:00 am ET SAN DIEGO, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (

      1/29/25 7:00:00 AM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zentalis Pharmaceuticals Provides Update on Azenosertib Clinical Development Program

      FDA has placed a partial clinical hold on ZN-c3-001, DENALI and TETON monotherapy studies of azenosertib Monotherapy data to be presented in the second half of 2024 Conference call to be held today, June 18, 8:00 am ET SAN DIEGO, June 18, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the following studies of azenosertib: the Phase 1 ZN-c3-001 dose-escalation study in solid tumors, the

      6/18/24 7:00:00 AM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zentalis Announces Intermittent Azenosertib Monotherapy Dosing Nearly Doubles Efficacy Over Continuous Dosing

       ORR of 36.8% in heavily pretreated platinum-resistant ovarian cancer and USC patients treated with intermittent dosing Establishes monotherapy RP2D of 400 mg QD with 5:2 dosing schedule; New RP2D more than doubles exposure levels, maintains safety and improves tolerability with no treatment-related discontinuations Company plans to update efficacy data from Phase 1 monotherapy dose optimization study and provide program timeline updates for three azenosertib Phase 2 monotherapy trials currently enrolling patients at the RP2D in the second half of 2023 Investor call at 8:00 a.m. ET today to review azenosertib monotherapy data supporting dose selection and chemotherapy combination da

      6/6/23 6:00:00 AM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care